Market Overview
OpenAI reported reaching a $40 billion annualized revenue run rate while launching a high-speed inference mode, even as Netflix pulled back from internal game development. In financial markets, Bank of America announced a $1.9 billion investment in India's Jio Credit, and Frasers Group rescued luxury retailer Harvey Nichols from administration.
OpenAI's annualized revenue run rate has surpassed $40 billion, roughly doubling its level from the end of 2025 ahead of a planned initial public offering. Co-founder and President GregBrockman informed employees that monthly revenue grew by more than 20% in July alone, driven by surging demand for coding tools like Codex, enterprise offerings such as ChatGPT Work, consumer subscriptions, and an emerging advertising business. The rapid acceleration brings the company's financial pace in line with rival Anthropic, which reported a $47 billion run rate in May, though differing accounting methods complicate direct comparisons. Both artificial intelligence pioneers have filed confidential paperwork for public market debuts, with Anthropic expected to list as early as the fall. To protect its market share against Anthropic and lower-cost alternatives, OpenAI has reduced prices on select models and overhauled its commercial leadership by appointing Dali Rajic as chief revenue officer.
Ten pharmacy benefit managers and the Pharmaceutical Care Management Association agreed Thursday to display TrumpRx cash prices within their benefit tools. The participating companies, including industry heavyweights CVS Health, OptumRx, and Express Scripts, will list TrumpRx prices alongside plan benefit prices for in-network prescriptions. Patients across commercial, Medicare, and Medicaid plans will be able to view these price comparisons using real-time benefit tools or platform features. CMS Administrator Dr. Mehmet Oz endorsed the move as a way to boost market competition and lower consumer costs. The Trump administration launched the TrumpRx platform earlier this year, building on prior expansions that added hundreds of generic drugs to the portal.
Bridgeline Digital reported fiscal third-quarter revenue of $3.9 million, missing the $4.7 million Wall Street consensus while edging past the $3.8 million posted a year earlier. The software maker posted a per-share loss of $0.04 for the period ended June 30, 2026, widening from a loss of $0.07 a year prior. Core product revenue rose 13% to $2.4 million, driven by demand for its HawkSearch platform and AI-powered marketing tools. This core segment now accounts for 62% of total revenue, up from 57% in the prior-year period, helping offset flat subscription revenue of $3.1 million. Operating expenses declined to $3.0 million from $3.2 million, allowing the absolute net loss to narrow to $500,000 from $800,000. Adjusted EBITDA improved to a loss of $102,000 from a loss of $330,000. During the quarter, the company signed 19 subscription contracts totaling $1.7 million in contract value and over $370,000 in annual recurring revenue.